These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12717339)

  • 1. Alefacept (Amevive) for treatment of psoriasis.
    Med Lett Drugs Ther; 2003 Apr; 45(1154):31-2. PubMed ID: 12717339
    [No Abstract]   [Full Text] [Related]  

  • 2. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
    Ellis CN; Krueger GG;
    N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
    Ortonne JP; Prinz JC
    Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of alefacept in elderly patients and other special populations.
    Gottlieb AB; Boehncke WH; Darif M
    J Drugs Dermatol; 2005; 4(6):718-24. PubMed ID: 16302557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current concepts and review of alefacept in the treatment of psoriasis.
    Krueger GG
    Dermatol Clin; 2004 Oct; 22(4):407-26, viii. PubMed ID: 15450337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remittive effects of intramuscular alefacept in psoriasis.
    Gordon KB; Langley RG
    J Drugs Dermatol; 2003 Dec; 2(6):624-8. PubMed ID: 14711140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
    Ortonne JP
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of alefacept in the treatment of psoriasis.
    Wong VK; Lebwohl M
    Skin Therapy Lett; 2003 Sep; 8(6):1-2, 7. PubMed ID: 14610613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical update on alefacept: consideration for use in patients with psoriasis.
    Gade JN
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
    Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
    J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alefacept: a novel biologic in the treatment of psoriasis.
    Liu CM; McKenna JK; Krueger GG
    Drugs Today (Barc); 2004 Dec; 40(12):961-74. PubMed ID: 15645008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
    Ortonne JP; Khemis A; Koo JY; Choi J
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
    Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
    Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and use of alefacept to treat psoriasis.
    Krueger GG; Callis KP
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S87-97. PubMed ID: 12894131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alefacept for chronic plaque psoriasis: a selective therapy with long-lasting disease remissions and an encouraging safety profile.
    Leone G; Rolston K; Spaulding G
    Dermatol Nurs; 2003 Jun; 15(3):216-20, 224-5; quiz 226. PubMed ID: 12875010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
    Bovenschen HJ; Gerritsen WJ; de Jong EM; van de Kerkhof PC
    Acta Derm Venereol; 2006; 86(3):281-2. PubMed ID: 16710605
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of palmoplantar psoriasis with intramuscular alefacept.
    Myers W; Christiansen L; Gottlieb AB
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S127-9. PubMed ID: 16021161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
    Ortonne JP; Lebwohl M; Em Griffiths C;
    Eur J Dermatol; 2003; 13(2):117-23. PubMed ID: 12695125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
    Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
    J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.